Massmutual Trust Co. FSB ADV Trims Stake in Pfizer Inc. (NYSE:PFE)

Massmutual Trust Co. FSB ADV lessened its position in Pfizer Inc. (NYSE:PFE) by 15.4% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 160,501 shares of the biopharmaceutical company’s stock after selling 29,191 shares during the quarter. Massmutual Trust Co. FSB ADV’s holdings in Pfizer were worth $4,454,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. VisionPoint Advisory Group LLC boosted its stake in Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares in the last quarter. GoalVest Advisory LLC increased its holdings in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares in the last quarter. Creekmur Asset Management LLC purchased a new position in shares of Pfizer in the 4th quarter worth about $32,000. Tennessee Valley Asset Management Partners bought a new position in shares of Pfizer in the fourth quarter worth approximately $36,000. Finally, DiNuzzo Private Wealth Inc. bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $37,000. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent analyst reports. Guggenheim started coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. BMO Capital Markets reissued an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Finally, Morgan Stanley lifted their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $35.86.

Pfizer Price Performance

Shares of Pfizer stock opened at $27.74 on Friday. The firm has a market cap of $157.19 billion, a PE ratio of -462.26, a PEG ratio of 1.08 and a beta of 0.70. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $39.24. The stock has a 50 day moving average of $27.63 and a 200 day moving average of $27.73. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The company had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter in the previous year, the business posted $1.23 earnings per share. Pfizer’s quarterly revenue was down 19.5% on a year-over-year basis. On average, research analysts expect that Pfizer Inc. will post 2.38 EPS for the current fiscal year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, June 14th. Stockholders of record on Friday, May 10th were issued a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.06%. The ex-dividend date of this dividend was Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.